Enoblituzumab (Anti-B7-H3 / CD276)
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2626 |
| Sku # | A2626-1mg*25 |
| Pricing | 1mg*25, $2970.00 |